Celldex Therapeutics (CLDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -258,757 | -177,440 | -110,396 | -53,796 | -157,863 |
| Depreciation Amortization | -2,475 | -2,409 | -2,215 | -1,400 | -12,572 |
| Accounts receivable | -1,315 | 610 | 610 | -364 | 1,928 |
| Other Working Capital | 14,058 | 5,524 | -4,279 | -8,496 | -21,601 |
| Other Operating Activity | 37,544 | 26,710 | 17,903 | 9,684 | 32,330 |
| Operating Cash Flow | $-210,945 | $-147,005 | $-98,377 | $-54,372 | $-157,778 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 211,786 | 155,080 | 93,793 | 43,215 | -288,210 |
| PPE Investments | -2,714 | -1,433 | -993 | -265 | -1,919 |
| Investing Cash Flow | $209,072 | $153,647 | $92,800 | $42,950 | $-290,129 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,388 | 1,039 | 265 | 202 | 441,449 |
| Financing Cash Flow | $2,388 | $1,039 | $265 | $202 | $441,449 |
| Beginning Cash Position | 28,356 | 28,356 | 28,356 | 28,356 | 34,814 |
| End Cash Position | 28,871 | 36,037 | 23,044 | 17,136 | 28,356 |
| Net Cash Flow | $515 | $7,681 | $-5,312 | $-11,220 | $-6,458 |
| Free Cash Flow | |||||
| Operating Cash Flow | -210,945 | -147,005 | -98,377 | -54,372 | -157,778 |
| Capital Expenditure | -2,714 | -1,433 | -993 | -265 | -1,919 |
| Free Cash Flow | -213,659 | -148,438 | -99,370 | -54,637 | -159,697 |